Endolymphatic sac tumor: case report and review of the literature
© Sun et al; licensee BioMed Central Ltd. 2012
Received: 16 February 2012
Accepted: 2 April 2012
Published: 2 April 2012
Endolymphatic sac tumor (ELST) is a rare neoplasm which can be encountered sporadically or in Von Hippel-Lindau (VHL) disease. Here we report a sporadic case of ELST in 31-year-old man. Neither the symptoms nor a family history of VHL disease were found in the patient. CT imaging demonstrated an expansile lytic lesion of the mastoid process of the left petrous bone. MR scanning revealed a 5.2 cm × 4.7 cm × 4.2 cm mass which showed hyperintensity on T1- and T2-weighted images. Histologic sections showed a papillary, cystic or glandular architecture. The papillary and glandular structures were lined by a single layer of flattened cuboidal-to-columnar cells. The stroma of the papillary fronds was richly vascularized and chronically inflamed. The tumor showed diffusely positive reactivity with cytokeratin (Pan), cytokeratin 19, cytokeratin 5/6, cytokeratin 7, EMA, vimentin, CD56, and NSE and also showed variable reactivity with glial fibrillary acidic protein (GFAP) and VEGF. The Ki-67 immunostain showed a proliferation index of < 1%. Because the mass was large, it was difficult to extirpate surgically. After surgery, the patient underwent gamma-knife radiosurgery for residual tumor. The findings indicate that ELST is a rare neoplasm with benign histopathological appearance and clinically destructive behavior. Because of the rarity of this tumor, it can easily be confused with other tumors such as paraganglioma, middle ear adenoma, adenocarcinoma, papillary carcinoma of thyroid or choroid plexus papilloma. Owing to its locally aggressive nature, it is difficult to extirpate surgically when it is large.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7973320646763012
Endolymphatic sac tumor (ELST) is a rare neoplasm with benign histopathological appearance and clinically destructive behavior which occurs in the skull base and frequently invades the posterior petrous bone, the mastoid, semicircular canal, cerebellopontine angle structures and cranial nerve. It is synonymous with Heffner tumor, low grade adenocarcinoma of endolymphatic sac origin, and aggressive papillary middle ear tumor according to the recently published World Health Organization tumor classification. These tumors can be encountered sporadically or in Von Hippel-Lindau (VHL) disease. Because of the rarity of this tumor, it can easily be confused with other tumors such as paraganglioma, middle ear adenoma, adenocarcinoma, papillary carcinoma of thyroid or choroid plexus papilloma. This report presents a 31-year-old male patient with endolymphatic sac tumor who was initially diagnosed with paraganglioma, with the following objectives: 1) to improve understanding of the variable clinical presentation of endolymphatic sac tumor, and 2) to identify histomorphological and immunohistochemical features of endolymphatic sac tumor.
Materials and methods
Formalin-fixed, paraffin-embedded tissues from the ELST was available. These were routinely processed and stained with hematoxylin and eosin (H&E). In addition to H&E, selected sections were stained with periodic acid-Schiff (PAS).
An immunohistochemical study was performed by EnVision method. The antibodies used were cytokeratin (Pan), epithelial membrane antigen (EMA), cytokeratin 19, cytokeratin 5/6, cytokeratin 7, vimentin, CD56, glial fibrillary acidic protein (GFAP), NSE, VEGF, S-100, CgA, Syn, TTF-1, thyroglobulin, calretinin and Ki-67 (DakoCytomation, Glostrup, Denmark). For antigen retrieval, slides were boiled with citrate buffer (0.01 mol/L, pH6.0) under high pressure for all the antigens. Appropriate positive and negative control experiments were performed.
Grossly, the specimen was received as an aggregate of pale pink fragments that were noted to be moderate in consistency. It was 5 cm × 4 cm × 2 cm in size.
Endolymphatic sac tumor is a primary neoplasm of the temporal bone which is described in patients as young as 4 years and as old as 85 years [1–8]. Mean age of patients without VHL disease was 52.5 years, whereas in 46 patients with VHL disease the mean age was 31.3 years. Patients with VHL disease were more likely to be female (female-to male ratio of 2:1 for VHL disease patients versus 1:1 for non- VHL disease patients) . Patients characteristically present with unilateral sensorineural hearing loss, tinnitus, otalgia, otorrhea, vertigo, ataxia, and facial nerve paresis. Meniere syndrome is uncommon. Large tumors growing along the posteromedial vector may cause symptoms secondary to cerebellopontine angle invasion. An indolent clinical course and long-standing symptom history are typical. The imaging hallmark of ELST is the presence of a retrolabyrinthine mass associated with osseous erosion. CT imaging demonstrated an expansile lytic lesion of the mastoid process of the petrous bone which extended to involve both the posterior fossa as well as the middle ear. In some case, the core of the tumor appeared isointense with brain on both the T1- and T2-weighted images with slight enhancement after intravenous gadolinium . Our case showed hyperintensity on T1- and T2-weighted images and axial postcontrast T1-weighted MR scan showed a heterogeneous enhancing mass. The periphery of the lesion appeared markedly hyperintense on the T2-weighted images. This might represent hemorrhage (extracellular methemoglobin) or cystic areas with high protein within the lesion.
Endolymphatic sac tumors are known to occur more frequently in patients with VHL disease, with up to 16 percent of patients with VHL disease harboring an ELST  Patients with VHL disease are more likely to have bilateral ELSTs. VHL disease is an autosomal dominant syndrome due to deletions or mutations in the VHL gene located on short arm of chromosome 3(3p25-p26) . The normal VHL gene is a tumor suppressor gene and it seems likely that the diminution of tumor suppression activity which results from the mutation of that gene leads to the various manifestations of the disease: renal cysts and renal carcinoma, pheochromocytoma, pancreatic cysts, neuroendocrine tumors, cystadenomas of the reproductive adnexal organs, and hemangioblastomas of the cerebellum, spinal cord, brain stem, and retina. VHL gene mutations have been shown both in ELSTs associated with VHL disease and in sporadic cases. Gene analysis performed to a patient with ELST who presented with a medical and family history of VHL disease showed mutation in VHL gene, resulting in C to T exchange at position 194, the consequence of which is an amino acid exchange S65L . Sporadic cases of endolymphatic sac tumor without VHL disease also showed VHL gene mutation similar to that in the germ line of patients with the disease according to Hamazaki's study .
The origin of endolymphatic sac tumors remains controversial for many years. Several reports mentioned the mastoid or middle ear epithelium as origin of these tumors [4, 13, 14]. Only recently, convincing anatomic, morphological and immunohistochemical arguments exist for an endolymphatic sac origin (inner-ear origin). The tumor was first identified during sac decompression surgery in 1984 . In 1989 Heffner described a new pathological entity of the endolymphatic sac. This tumor grew slowly, destroyed the temporal bone, and showed papillary cystic and glandular patterns. He also found the epicenters of the tumors in his cases and in other reports to have the same anatomic location, in the area of the vestibular aqueduct and endolymphatic sac of the posterior petrous bone. In addition, there are some common histologic features between these tumors and the normal endolymphatic sac. So he speculated that the tumor arise in the endolymphatic sac . In 2004 Lonser described a 40-year-old man with von Hippel Lindau disease showing bilateral endolymphatic sac tumors. On the right side there was an extensive endolymphatic sac tumor invading the temporal bone to involve structures as far distant as mastoid air cells. On the left side illustrations define a papillary tumor confined to the lumen of endolymphatic ducts and sacs (EDS), extending from the endolymphatic duct to the extraosseous sac on the dural surface. This case described here confirms the concept of an origin of the neoplasm in the endolymphatic sac . The endolymphatic duct arises in the posteroinferior part of the vestibule of the inner ear as the result of the union of an endolymph-containing epithelial tube from the saccule and one from the utricle. This tube passes into a bony canal, the vestibular aqueduct, and extends posteriorly and laterally. It soon widens in a superior-inferior plane but not in an anteroposterior one, and is here known as the endolymphatic sac. A study of the epithelium of normal human mature endolymphatic ducts and sacs (EDSs) in archival temporal bone sections showed hyperplastic tubular outgrowths, usually situated in the intraosseous portion of the endolymphatic sac, in most cases. So the intraosseous portion of the endolymphatic sac maybe the the origin of endolymhoatic sac tumor . The endolymphatic sac is derived from neuroectoderm and is located subjacent to the posteromedial surface of the temporal bone. There are 4 potential vectors for endolymphatic sac tumor extension: posteromedially into the cerebellopontine angle, laterally toward the middle ear, superiorly toward the middle cranial fossa, and anteromedially along the petrous ridge toward the cavernous and sphenoid sinuses. Individual examples may grow primarily along one of these vectors or along multiple vectors .
Histopathologically, these tumors are composed of papillary and cystic proliferations lined by a single layer of flattened cuboidal-to-columnar cells. The nuclei of the epithelial layer show slight variability in size and shape. Mitotic activity is rare. The stroma of the papillary fronds was richly vascularized and chronically inflamed. Large areas of hypocellular fibrosis, hemorrhage, cholesterol clefts, and associated reactive changes are frequently found. Because of the rarity of this tumor, that can easily be confused with other papillary lesions on histopathologic grounds. The histopathological differential diagnosises of ELST include paraganglioma, chorioid plexus papilloma, papillary ependymoma, papillary mesohyloma, middle ear adenoma, and metastatic carcinoma of the thyroid, kidney, prostate, lung, and breast. Paragangliomas of the middle ear are cytologically benign and may demonstrate papillary structures and cuboidal cells with eosinophilic cytoplasm. However, paraganglioma cells are positive for chromogranin and synaptophysin, and at least focally they are arranged in characteristic nests. This tumor we report was positive for cytokeratin (Pan), cytokeratin 19, cytokeratin 5/6, cytokeratin 7, and epithelial membrane antigen, so it is easy to differentiate them by immunohistochemistry. Chorioid plexus papilloma may be histologically similar to ELST, but it originates in the ventricle and does not invade bone. To aid in the differentiation between papillary tumors of endolymphatic sac and duct origin and those arising from ectopic choroid plexus, an immunohistochemical study using stains for transthyretin (TTR), cytokeratins, S-100 protein, EMA, and GFAP was carried out on archival specimens of normal and neoplastic endolymphatic sac and duct and choroid plexus epithelium. Transthyretin, a marker for choroid plexus epithelium, was found to show differential expression between choroid plexus papillomas and aggressive papillary tumors of the endolymphatic sac or duct. Therefore the use of TTR in concert with other immunohistochemical stains appear to aid in the differentiation between intracranial and intratemporal papillary tumors arising from choroid plexus and endolymphatic sac or duct epithelium . Papillary ependymoma shows discohesive growth, pseudopapillae, and perivascular pseudorosettes. Finger like projections are lined by single or multiple layers of cuboidal tumor cells with smooth contiguous surfaces and with GFAP-positive tumor cell processes. Papillary mesohyloma occurs in pelvic peritoneum, gastrocolic omentum, mesenterium, pleura and is positive to CK5/6, calretinin, and vimentin. Middle ear adenomas are nonpapillary, are confined to the middle ear and mastoid, and rarely show bone destruction. Currently, considerations of metastases from thyroid, breast, and prostate can be eliminated by immunohistochemistry.
Treatment of ELST involves local resection of the tumor or radical mastoidectomy alone, or in combination with radiotherapy. Early surgical excision is the best treatment when the tumor is small. Remission may last for years. When the tumor is large, complete excision is nearly impossible due to the anatomic complexity of the endolymphatic sac and distinct patterns of extension. Local recurrence after surgery can occur. In advanced cases radiotherapy alone may be the sole option, although there are no studies focusing on the role of adjuvant radiotherapy. Because endolymphatic sac tumor is richly vascularized, some scholars suggest that preoperative embolization may be helpful. In our case, the mass was large, destructed the mastoid process of the left petrous bone and extended to involve both the left medial mastoid as well as the middle ear, so it was difficult to extirpate surgically. After surgery, the patient underwent gamma-knife radiosurgery for residual tumor.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Kupferman ME, Bigelow DC, Carpentieri DF, et al.: Endolymphatic sac tumor in a 4-year-old boy. Otol Neurotol. 2004, 25: 782-786. 10.1097/00129492-200409000-00022.View ArticlePubMedGoogle Scholar
- Bambakidis NC, Megerian CA, Ratcheson RA: Differential grading of endolymphatie sac tumor extension by virtue of von Hippel-Lindau disease status. Otol Neurotol. 2004, 25: 773-781. 10.1097/00129492-200409000-00021.View ArticlePubMedGoogle Scholar
- Skalova A, Sima R, Bohus P, et al.: Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone) Report of two cases with analysis of the VHL gene. Pathol Res Pract. 2008, 204: 599-606. 10.1016/j.prp.2008.01.016.View ArticlePubMedGoogle Scholar
- Gaffey MJ, Mills SE, Fechner RE, et al.: Aggressive papillary middle-ear tumor, A clinicopathologic entity distinct from middle-ear adenoma. Am J Surg Pathol. 1988, 12: 790-797. 10.1097/00000478-198810000-00009.View ArticlePubMedGoogle Scholar
- Cazals-Hatem D, Henin D, Bouccara D, et al.: Endolymphatic sac tumor: a rare tumor of internal ear. Report of two cases. Ann Pathol. 2000, 20: 349-352.PubMedGoogle Scholar
- Jagannathan J, Butman JA, Lonser RR, et al.: Endolymphatic sac tumor demonstrated by intralabyrinthine hemorrhage. Case report. Neurosurgery. 2007, 107: 421-425. 10.3171/JNS-07/08/0421.View ArticleGoogle Scholar
- Bae CW, Cho YH, Chung JW, et al.: Endolymphatic sac tumors: report of four cases. J Korean Neurosurg Soc. 2008, 44: 268-272. 10.3340/jkns.2008.44.4.268.PubMed CentralView ArticlePubMedGoogle Scholar
- Krzysztolik K, Cybulski C, Sagan L, et al.: Endolymphatic sac tumours and von Hippel-Lindau disease - case report, molecular analysis and histopathological characterization. Folia Neuropathol. 2009, 47: 75-80.PubMedGoogle Scholar
- Ho VT, Rao VM, Doan HT, et al.: Low-grade adenocarcinoma of probable endolymphatic sac origin: CT and MR appearance. AJNR Am J Neuroradiol. 1996, 17: 168-170.PubMedGoogle Scholar
- Choo D, Shotland L, Mastroianni M, et al.: Endolymphatic sac tumors in von Hippel-Lindau disease. J Neurosurg. 2004, 100: 480-487. 10.3171/jns.2004.100.3.0480.View ArticlePubMedGoogle Scholar
- Friedrich CA: Von Hippel-Lindau syndrome. A pleomorphic condition. Cancer. 1999, 86: 2478-2482. 10.1002/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5.View ArticlePubMedGoogle Scholar
- Hamazaki S, Yoshida M, Yao M, et al.: Mutation of von Hippel-Lindau tumor suppressor gene in a sporadic endolymphatic sac tumor. Hum Pathol. 2001, 32: 1272-1276. 10.1053/hupa.2001.28961.View ArticlePubMedGoogle Scholar
- Schuller DE, Conley JJ, Goodman JH, et al.: Primary adenocarcinoma of the middle ear. Otolaryngol Head Neck Surg. 1983, 91: 280-283.PubMedGoogle Scholar
- Pallanch JF, McDonald TJ, Weiland LH, et al.: Adenocarcinoma and adenoma of the middle ear. Laryngoscope. 1982, 92: 47-53.View ArticlePubMedGoogle Scholar
- Hassard AD, Boudreau SF, Cron CC: Adenoma of the endolymphatic sac. Otolaryngol J. 1984, 13: 213-216.Google Scholar
- Heffner DK: Low-grade adanoearcinoma of probable endolymphatic sac orisin a elinicopathologic study of 20 cases. Cancer. 1989, 64: 2292-2302. 10.1002/1097-0142(19891201)64:11<2292::AID-CNCR2820641119>3.0.CO;2-#.View ArticlePubMedGoogle Scholar
- Lonser RR, Kim HJ, Butman JA, et al.: Tumors of the endolymphatic sac in von Hippel-Lindau disease. N Engl J Med. 2004, 350: 2481-2486. 10.1056/NEJMoa040666.View ArticlePubMedGoogle Scholar
- Michaels L: Origin of endolymphatic sac tumor. Head Neck Pathol. 2007, 1: 104-111. 10.1007/s12105-007-0016-3.PubMed CentralView ArticlePubMedGoogle Scholar
- Bell D, Gidley P, Levine N, et al.: Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): sine qua non radiology-pathology and the University of Texas MD Anderson Cancer Center experience. Ann Diagn Pathol. 2011, 15: 117-123. 10.1016/j.anndiagpath.2010.08.009.View ArticlePubMedGoogle Scholar
- Megerian CA, Pilch BZ, Bhan AK, et al.: Differential expression of transthyretin in papillary tumors of the endolymphatic sac and choroid plexus. Laryngoscope. 1997, 107: 216-221. 10.1097/00005537-199702000-00014.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.